TCV 309

Drug Profile

TCV 309

Latest Information Update: 10 Oct 2000

Price : $50

At a glance

  • Originator Takeda
  • Class Antipsoriatics; Antiulcers
  • Mechanism of Action Platelet activating factor inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Atopic dermatitis; Blood coagulation disorders; Myocardial infarction; Peptic ulcer; Psoriasis; Shock

Most Recent Events

  • 10 Oct 2000 Discontinued-II for Shock in Japan (Unknown route)
  • 10 Oct 2000 Discontinued-Preclinical for Peptic ulcer in Canada (Unknown route)
  • 10 Oct 2000 Discontinued-Preclinical for Myocardial infarction in Canada (Unknown route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top